Key Insights
The Global Psoriasis Drugs Market is poised for substantial growth, currently valued at USD 7.59 billion in 2025 and projected to expand at a robust Compound Annual Growth Rate (CAGR) of 15.02% through 2033. This significant expansion is propelled by a confluence of factors, including an increasing global prevalence of psoriasis, heightened awareness among patients and healthcare providers, and continuous advancements in drug discovery and development. Biologic drugs, particularly TNF Alpha Inhibitors and Interleukin Inhibitors, are leading the charge, offering more targeted and effective treatment options compared to traditional therapies. The rising incidence of chronic inflammatory diseases, coupled with improved diagnostic capabilities and a growing emphasis on patient quality of life, further fuels market demand. North America and Europe currently dominate the market share, driven by advanced healthcare infrastructure, higher disposable incomes, and early adoption of novel therapeutics.
Global Psoriasis Drugs Market Market Size (In Billion)
Emerging trends indicate a shift towards personalized medicine and combination therapies to address the complexities of psoriasis management. While the market exhibits strong growth, certain restraints such as the high cost of advanced biologic treatments and potential side effects necessitate careful consideration. However, ongoing research into novel drug mechanisms, including PDE4 Inhibitors and other targeted therapies, alongside the expanding patient base in the Asia Pacific region, are expected to mitigate these challenges. Pharmaceutical giants are actively investing in R&D and strategic collaborations to capture market share, introducing innovative formulations and delivery systems. The increasing demand for long-term management solutions for chronic conditions like psoriasis underscores the sustained momentum and promising future of this dynamic market.
Global Psoriasis Drugs Market Company Market Share
This report offers an in-depth analysis of the global psoriasis drugs market, projected to reach an impressive valuation of approximately $XX billion by 2033. With a robust compound annual growth rate (CAGR) of xx% from 2025 to 2033, the market is driven by increasing prevalence of psoriasis, advancements in treatment modalities, and growing patient awareness. We delve into market segmentation by Type of Treatment, Mechanism of Action, and Route of Administration, providing critical insights for stakeholders. This report covers the historical period from 2019 to 2024, with the base year and estimated year both set as 2025.
Global Psoriasis Drugs Market Market Concentration & Innovation
The global psoriasis drugs market exhibits a moderate to high level of concentration, with several multinational pharmaceutical giants dominating the landscape. Innovation serves as a primary driver, fueled by extensive research and development into novel therapeutic targets and drug delivery systems. Regulatory frameworks, including FDA and EMA approvals, significantly influence market entry and product lifecycle. The availability of biological drugs and advancements in small molecule inhibitors have reshaped treatment paradigms, impacting market share. Product substitutes, while existing in the form of lifestyle management and alternative therapies, are increasingly being overshadowed by the efficacy of pharmaceutical interventions, particularly biologics. End-user trends indicate a growing demand for targeted therapies with improved safety profiles and convenient administration routes. Mergers and acquisitions (M&A) activities, characterized by significant deal values often in the billions, are strategic moves by leading players to expand their product portfolios and market reach. For instance, major M&A activities have seen companies like AbbVie Inc. and Johnson & Johnson (Janssen Biotech Inc.) consolidate their positions. The market share distribution is dynamic, with key players continuously vying for dominance through innovation and strategic partnerships.
Global Psoriasis Drugs Market Industry Trends & Insights
The global psoriasis drugs market is experiencing significant expansion, propelled by a confluence of escalating psoriasis prevalence worldwide and substantial advancements in therapeutic interventions. The increasing incidence of this chronic autoimmune condition, affecting millions globally, directly translates into a heightened demand for effective treatment options. Technological disruptions, particularly in the realm of biopharmaceuticals and targeted therapies, are revolutionizing psoriasis management. The development of highly selective biologic agents, such as interleukin inhibitors and TNF alpha inhibitors, has offered unprecedented efficacy and improved quality of life for patients with moderate to severe psoriasis. These innovations are leading to a shift away from traditional systemic therapies towards more personalized treatment approaches. Consumer preferences are increasingly leaning towards treatments that offer better safety profiles, fewer side effects, and less frequent administration, driving the adoption of newer generation drugs. Competitive dynamics are fierce, with pharmaceutical giants heavily investing in research and development to secure a larger market share. Key players are focusing on expanding their pipelines with innovative molecules and exploring new therapeutic targets to address unmet medical needs. The market penetration of advanced therapies is steadily rising, indicating a growing acceptance and physician preference for these potent treatments. The overall CAGR is projected to remain robust, underscoring the market's sustained growth trajectory. Strategic collaborations and licensing agreements are also prevalent, facilitating the rapid commercialization of novel drug candidates. The market is characterized by a continuous cycle of innovation and competition, ensuring a dynamic and evolving landscape for psoriasis therapeutics.
Dominant Markets & Segments in Global Psoriasis Drugs Market
The Biologic Drugs segment within the Type of Treatment category stands out as the dominant force in the global psoriasis drugs market. This dominance is primarily attributed to their high efficacy in treating moderate to severe plaque psoriasis, offering significant improvements in skin clearance and patient quality of life. Within biologic drugs, Interleukin Inhibitors, particularly Secukinumab and Ustekinumab, have emerged as leading therapeutic agents due to their targeted mechanism of action and favorable safety profiles compared to earlier biologic classes. The TNF Alpha Inhibitors, including Adalimumab and Infiximab, also maintain a significant market share.
North America, particularly the United States, consistently represents the dominant geographic region in the psoriasis drugs market. This leadership is fueled by:
- High prevalence of psoriasis: A large patient population seeking advanced treatments.
- Robust healthcare infrastructure: Enabling widespread access to innovative therapies.
- Favorable reimbursement policies: Supporting the adoption of expensive biologic drugs.
- Strong presence of key pharmaceutical companies: Driving research, development, and commercialization.
In terms of Mechanism of Action, Interleukin Inhibitors are experiencing the most rapid growth, driven by their targeted approach and improved patient outcomes. TNF Alpha Inhibitors continue to hold a substantial market share due to their established efficacy and broad clinical use.
Regarding the Route of Administration, Parenteral administration remains dominant, primarily due to the nature of biologic drugs which are often administered via injection or infusion. However, there is a growing trend towards the development and adoption of Oral therapies, exemplified by the success of PDE4 Inhibitors like Apremilast, offering greater convenience for patients. Topical Therapies, while important for milder forms of psoriasis, hold a smaller market share in the overall psoriasis drugs market but are experiencing innovation with the introduction of novel steroid-free formulations.
The interplay of these factors—high efficacy biologics, advanced targeted therapies, strong market access in key regions like North America, and continuous innovation across all treatment modalities—solidifies the dominance of specific segments and markets within the global psoriasis drugs landscape.
Global Psoriasis Drugs Market Product Developments
Product developments in the psoriasis drugs market are characterized by a relentless pursuit of enhanced efficacy, improved safety profiles, and greater patient convenience. Innovations are heavily focused on next-generation biologic agents targeting specific inflammatory pathways with greater precision, such as novel interleukin inhibitors and cytokine modulators. The development of small molecule drugs with oral administration offers a significant competitive advantage by providing a non-invasive treatment option. Furthermore, advancements in topical therapies are leading to steroid-free formulations that minimize long-term side effects, appealing to a growing segment of patients and healthcare providers. These product innovations are critical for expanding market reach and addressing unmet patient needs.
Report Scope & Segmentation Analysis
This report meticulously segments the global psoriasis drugs market across key dimensions to provide granular insights. The Type of Treatment segmentation encompasses Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies, each analyzed for their market size and growth projections. The Mechanism of Action segmentation delves into specific drug classes including TNF Alpha Inhibitors (with sub-categories like Etanercept, Certolizumab Pegol, Adalimumab, Infiximab, Golimumab), PDE4 Inhibitors (Apremilast), and Interleukin Inhibitors (Secukinumab, Ustekinumab, Other Interleukin Inhibitors), along with Other Mechanisms of Action, detailing their respective market shares and competitive dynamics. The Route of Administration is categorized into Oral, Parenteral, and Topical, offering insights into patient preference and market accessibility. Each segment is analyzed with growth projections and competitive landscapes throughout the forecast period (2025–2033).
Key Drivers of Global Psoriasis Drugs Market Growth
Several key drivers are propelling the global psoriasis drugs market forward. The increasing global prevalence of psoriasis, attributed to lifestyle factors, genetic predispositions, and environmental triggers, directly expands the addressable patient population. Significant advancements in pharmaceutical research and development have led to the introduction of more effective and targeted biologic therapies, offering better disease control and improved patient outcomes. Growing patient awareness regarding psoriasis as a manageable chronic condition and the availability of diverse treatment options further fuels market demand. Moreover, supportive government initiatives and regulatory approvals for novel drugs contribute to market expansion by facilitating access and encouraging innovation.
Challenges in the Global Psoriasis Drugs Market Sector
Despite robust growth, the global psoriasis drugs market faces notable challenges. The high cost associated with biologic therapies remains a significant barrier to access for a considerable segment of the patient population, particularly in developing economies. Stringent and lengthy regulatory approval processes for new drugs can delay market entry and increase development costs for pharmaceutical companies. The emergence of biosimil drugs, while potentially increasing affordability, also intensifies competition and can impact the market share of originator products. Furthermore, the development of effective treatments for different subtypes and severities of psoriasis continues to be an area of ongoing research, highlighting the need for more personalized and comprehensive therapeutic solutions.
Emerging Opportunities in Global Psoriasis Drugs Market
Emerging opportunities in the global psoriasis drugs market are primarily centered around the development of novel therapeutic targets and delivery systems. The growing understanding of the underlying pathophysiology of psoriasis is paving the way for drugs targeting specific cytokines and inflammatory pathways with even greater precision. The expanding market for topical treatments, particularly steroid-free options, presents a significant opportunity due to their favorable safety profile for long-term use. Furthermore, the increasing focus on early intervention and disease management strategies, coupled with the growing adoption of digital health solutions for patient monitoring and adherence, offers avenues for market growth and enhanced patient care.
Leading Players in the Global Psoriasis Drugs Market Market
- Sun Pharmaceutical Industries Limited
- Celgene Corporation
- Novartis AG
- Amgen Inc
- Leo Pharma AS
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Biogen Idec
- UCB SA
- AstraZenca
- Merck and Co Inc
- Forward Pharma
- AbbVie Inc
- Johnson and Johnson (Janssen Biotech Inc )
- Boehringer Ingelheim
- Valeant Pharmaceuticals
- Stiefel Laboratories Inc
- Dr Reddy`s Laboratories
- Pfizer Inc
Key Developments in Global Psoriasis Drugs Market Industry
- July 2022: Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. This approval signifies a significant advancement in topical treatments.
- May 2022: Dermavant Sciences received United States Food and Drug Administration (FDA) approval for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class, highlighting a major trend towards safer topical options.
Strategic Outlook for Global Psoriasis Drugs Market Market
The strategic outlook for the global psoriasis drugs market is characterized by continued innovation, market expansion, and a focus on patient-centric solutions. Pharmaceutical companies are expected to invest heavily in research and development to discover and commercialize novel therapies targeting unmet needs, particularly for severe and recalcitrant psoriasis. The increasing demand for oral and convenient biologic options will drive product development. Strategic partnerships, collaborations, and acquisitions will remain crucial for companies to strengthen their portfolios and gain a competitive edge. Furthermore, the growing emphasis on real-world evidence and patient outcomes will shape market access and reimbursement strategies, creating a dynamic and evolving landscape for psoriasis therapeutics.
Global Psoriasis Drugs Market Segmentation
-
1. Type of Treatment
- 1.1. Biologic Drugs
- 1.2. Small Molecule Systemic Drugs
- 1.3. Tropical Therapies
-
2. Mechanism of Action
-
2.1. TNF Alpha Inhibitors
- 2.1.1. Etanercept
- 2.1.2. Certolizumab Pegol
- 2.1.3. Adalimumab
- 2.1.4. Infiximab
- 2.1.5. Golimumab
-
2.2. PDE4 Inhibitors
- 2.2.1. Apremilast
-
2.3. Interleukin Inhibitors
- 2.3.1. Secukinumab
- 2.3.2. Ustekinumab
- 2.3.3. Other Interleukin Inhibitors
- 2.4. Other Mechanisms of Action
-
2.1. TNF Alpha Inhibitors
-
3. Route of Administration
- 3.1. Oral
- 3.2. Parenteral
- 3.3. Topical
Global Psoriasis Drugs Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Global Psoriasis Drugs Market Regional Market Share
Geographic Coverage of Global Psoriasis Drugs Market
Global Psoriasis Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 15.02% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies; Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs
- 3.3. Market Restrains
- 3.3.1. Adverse Side Effects of Existing Medications; High Cost of Psoriasis Treatments; Extensive Drug Development and Approval Process
- 3.4. Market Trends
- 3.4.1. Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 5.1.1. Biologic Drugs
- 5.1.2. Small Molecule Systemic Drugs
- 5.1.3. Tropical Therapies
- 5.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 5.2.1. TNF Alpha Inhibitors
- 5.2.1.1. Etanercept
- 5.2.1.2. Certolizumab Pegol
- 5.2.1.3. Adalimumab
- 5.2.1.4. Infiximab
- 5.2.1.5. Golimumab
- 5.2.2. PDE4 Inhibitors
- 5.2.2.1. Apremilast
- 5.2.3. Interleukin Inhibitors
- 5.2.3.1. Secukinumab
- 5.2.3.2. Ustekinumab
- 5.2.3.3. Other Interleukin Inhibitors
- 5.2.4. Other Mechanisms of Action
- 5.2.1. TNF Alpha Inhibitors
- 5.3. Market Analysis, Insights and Forecast - by Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Topical
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 6. North America Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 6.1.1. Biologic Drugs
- 6.1.2. Small Molecule Systemic Drugs
- 6.1.3. Tropical Therapies
- 6.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 6.2.1. TNF Alpha Inhibitors
- 6.2.1.1. Etanercept
- 6.2.1.2. Certolizumab Pegol
- 6.2.1.3. Adalimumab
- 6.2.1.4. Infiximab
- 6.2.1.5. Golimumab
- 6.2.2. PDE4 Inhibitors
- 6.2.2.1. Apremilast
- 6.2.3. Interleukin Inhibitors
- 6.2.3.1. Secukinumab
- 6.2.3.2. Ustekinumab
- 6.2.3.3. Other Interleukin Inhibitors
- 6.2.4. Other Mechanisms of Action
- 6.2.1. TNF Alpha Inhibitors
- 6.3. Market Analysis, Insights and Forecast - by Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Topical
- 6.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 7. Europe Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 7.1.1. Biologic Drugs
- 7.1.2. Small Molecule Systemic Drugs
- 7.1.3. Tropical Therapies
- 7.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 7.2.1. TNF Alpha Inhibitors
- 7.2.1.1. Etanercept
- 7.2.1.2. Certolizumab Pegol
- 7.2.1.3. Adalimumab
- 7.2.1.4. Infiximab
- 7.2.1.5. Golimumab
- 7.2.2. PDE4 Inhibitors
- 7.2.2.1. Apremilast
- 7.2.3. Interleukin Inhibitors
- 7.2.3.1. Secukinumab
- 7.2.3.2. Ustekinumab
- 7.2.3.3. Other Interleukin Inhibitors
- 7.2.4. Other Mechanisms of Action
- 7.2.1. TNF Alpha Inhibitors
- 7.3. Market Analysis, Insights and Forecast - by Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Topical
- 7.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 8. Asia Pacific Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 8.1.1. Biologic Drugs
- 8.1.2. Small Molecule Systemic Drugs
- 8.1.3. Tropical Therapies
- 8.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 8.2.1. TNF Alpha Inhibitors
- 8.2.1.1. Etanercept
- 8.2.1.2. Certolizumab Pegol
- 8.2.1.3. Adalimumab
- 8.2.1.4. Infiximab
- 8.2.1.5. Golimumab
- 8.2.2. PDE4 Inhibitors
- 8.2.2.1. Apremilast
- 8.2.3. Interleukin Inhibitors
- 8.2.3.1. Secukinumab
- 8.2.3.2. Ustekinumab
- 8.2.3.3. Other Interleukin Inhibitors
- 8.2.4. Other Mechanisms of Action
- 8.2.1. TNF Alpha Inhibitors
- 8.3. Market Analysis, Insights and Forecast - by Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Topical
- 8.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 9. Middle East and Africa Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 9.1.1. Biologic Drugs
- 9.1.2. Small Molecule Systemic Drugs
- 9.1.3. Tropical Therapies
- 9.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 9.2.1. TNF Alpha Inhibitors
- 9.2.1.1. Etanercept
- 9.2.1.2. Certolizumab Pegol
- 9.2.1.3. Adalimumab
- 9.2.1.4. Infiximab
- 9.2.1.5. Golimumab
- 9.2.2. PDE4 Inhibitors
- 9.2.2.1. Apremilast
- 9.2.3. Interleukin Inhibitors
- 9.2.3.1. Secukinumab
- 9.2.3.2. Ustekinumab
- 9.2.3.3. Other Interleukin Inhibitors
- 9.2.4. Other Mechanisms of Action
- 9.2.1. TNF Alpha Inhibitors
- 9.3. Market Analysis, Insights and Forecast - by Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Topical
- 9.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 10. South America Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 10.1.1. Biologic Drugs
- 10.1.2. Small Molecule Systemic Drugs
- 10.1.3. Tropical Therapies
- 10.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 10.2.1. TNF Alpha Inhibitors
- 10.2.1.1. Etanercept
- 10.2.1.2. Certolizumab Pegol
- 10.2.1.3. Adalimumab
- 10.2.1.4. Infiximab
- 10.2.1.5. Golimumab
- 10.2.2. PDE4 Inhibitors
- 10.2.2.1. Apremilast
- 10.2.3. Interleukin Inhibitors
- 10.2.3.1. Secukinumab
- 10.2.3.2. Ustekinumab
- 10.2.3.3. Other Interleukin Inhibitors
- 10.2.4. Other Mechanisms of Action
- 10.2.1. TNF Alpha Inhibitors
- 10.3. Market Analysis, Insights and Forecast - by Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Topical
- 10.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Sun Pharmaceutical Industries Limited
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Celgene Corporation
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Novartis AG
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Amgen Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Leo Pharma AS
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Takeda Pharmaceutical Company Limited
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Eli Lilly and Company
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Biogen Idec
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 UCB SA
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 AstraZenca
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Merck and Co Inc
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Forward Pharma
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 AbbVie Inc
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 Johnson and Johnson (Janssen Biotech Inc )
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 Boehringer Ingelheim
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.16 Valeant Pharmaceuticals
- 11.2.16.1. Overview
- 11.2.16.2. Products
- 11.2.16.3. SWOT Analysis
- 11.2.16.4. Recent Developments
- 11.2.16.5. Financials (Based on Availability)
- 11.2.17 Stiefel Laboratories Inc
- 11.2.17.1. Overview
- 11.2.17.2. Products
- 11.2.17.3. SWOT Analysis
- 11.2.17.4. Recent Developments
- 11.2.17.5. Financials (Based on Availability)
- 11.2.18 Dr Reddy`s Laboratories
- 11.2.18.1. Overview
- 11.2.18.2. Products
- 11.2.18.3. SWOT Analysis
- 11.2.18.4. Recent Developments
- 11.2.18.5. Financials (Based on Availability)
- 11.2.19 Pfizer Inc
- 11.2.19.1. Overview
- 11.2.19.2. Products
- 11.2.19.3. SWOT Analysis
- 11.2.19.4. Recent Developments
- 11.2.19.5. Financials (Based on Availability)
- 11.2.1 Sun Pharmaceutical Industries Limited
List of Figures
- Figure 1: Global Global Psoriasis Drugs Market Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: Global Global Psoriasis Drugs Market Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 4: North America Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 5: North America Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 6: North America Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 7: North America Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 8: North America Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 9: North America Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 10: North America Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 11: North America Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 12: North America Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 13: North America Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 14: North America Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 15: North America Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 16: North America Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 17: North America Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 18: North America Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 19: Europe Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 20: Europe Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 21: Europe Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 22: Europe Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 23: Europe Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 24: Europe Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 25: Europe Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 26: Europe Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 27: Europe Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 28: Europe Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 29: Europe Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 30: Europe Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 31: Europe Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 32: Europe Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 33: Europe Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 34: Europe Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 35: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 36: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 37: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 38: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 39: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 40: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 41: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 42: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 43: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 44: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 45: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 46: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 47: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 48: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 49: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 50: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 51: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 52: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 53: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 54: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 55: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 56: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 57: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 58: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 59: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 60: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 61: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 62: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 63: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 64: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 65: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 66: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 67: South America Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 68: South America Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 69: South America Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 70: South America Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 71: South America Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 72: South America Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 73: South America Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 74: South America Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 75: South America Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 76: South America Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 77: South America Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 78: South America Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 79: South America Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 80: South America Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 81: South America Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 82: South America Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 2: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 3: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 4: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 5: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 6: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 7: Global Psoriasis Drugs Market Revenue billion Forecast, by Region 2020 & 2033
- Table 8: Global Psoriasis Drugs Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 9: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 10: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 11: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 12: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 13: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 14: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 15: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 16: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 17: United States Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: United States Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: Canada Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 20: Canada Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 21: Mexico Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 22: Mexico Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 24: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 25: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 26: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 27: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 28: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 29: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 30: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 31: Germany Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: Germany Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 33: United Kingdom Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: United Kingdom Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 35: France Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 36: France Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Italy Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Italy Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: Spain Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 40: Spain Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: Rest of Europe Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 42: Rest of Europe Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 44: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 45: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 46: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 47: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 48: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 49: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 50: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 51: China Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 52: China Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Japan Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 54: Japan Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: India Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 56: India Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 57: Australia Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 58: Australia Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 59: South Korea Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 60: South Korea Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Rest of Asia Pacific Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 62: Rest of Asia Pacific Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 64: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 65: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 66: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 67: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 68: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 69: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 70: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 71: GCC Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 72: GCC Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 73: South Africa Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 74: South Africa Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 75: Rest of Middle East and Africa Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 76: Rest of Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 77: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 78: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 79: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 80: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 81: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 82: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 83: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 84: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 85: Brazil Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 86: Brazil Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Argentina Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 88: Argentina Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 89: Rest of South America Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 90: Rest of South America Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Global Psoriasis Drugs Market?
The projected CAGR is approximately 15.02%.
2. Which companies are prominent players in the Global Psoriasis Drugs Market?
Key companies in the market include Sun Pharmaceutical Industries Limited, Celgene Corporation, Novartis AG, Amgen Inc, Leo Pharma AS, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Idec, UCB SA, AstraZenca, Merck and Co Inc, Forward Pharma, AbbVie Inc, Johnson and Johnson (Janssen Biotech Inc ), Boehringer Ingelheim, Valeant Pharmaceuticals, Stiefel Laboratories Inc, Dr Reddy`s Laboratories, Pfizer Inc.
3. What are the main segments of the Global Psoriasis Drugs Market?
The market segments include Type of Treatment, Mechanism of Action, Route of Administration.
4. Can you provide details about the market size?
The market size is estimated to be USD 7.59 billion as of 2022.
5. What are some drivers contributing to market growth?
Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies; Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs.
6. What are the notable trends driving market growth?
Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period.
7. Are there any restraints impacting market growth?
Adverse Side Effects of Existing Medications; High Cost of Psoriasis Treatments; Extensive Drug Development and Approval Process.
8. Can you provide examples of recent developments in the market?
In July 2022, Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Global Psoriasis Drugs Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Global Psoriasis Drugs Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Global Psoriasis Drugs Market?
To stay informed about further developments, trends, and reports in the Global Psoriasis Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence